Apigenin has shown growth inhibitory properties in breast cancer via apoptosis promotion via (a) activation of the caspase cascade; (b) blocking NF-κB and STAT3 signaling in breast cancer cells with HER2-overexpression; (c) eliminating both the PI3K and Akt kinase activity and modulation of the p14ARF-Mdm2-p53 pathway (Way et al., 2004; Agrawal et al., 2006; Choi and Kim, 2009; Seo et al., 2012). This evidence concerns the gene ERBB2 and breast cancer.